DISCLAIMER
These codes are currently under development by the LOINC team, and are subject to change prior to inclusion in a public release. It is possible that they may not be published in the next, or any, public release. They are provided here for informational purposes only.
SPECIAL USE
Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release.
Guidance for mapping to SARS-CoV-2 LOINC terms
Full list of LOINCs related to SARS-CoV-2/COVID-19
The page linked above includes an option to export terms in CSV format.
Receive email notices of new Special Use LOINC terms
scroll/swipe to view more columns
Created On | LOINC | Long Common Name | Special Use | Component | Prop | Time | System | Scale | Method | Shortname |
---|---|---|---|---|---|---|---|---|---|---|
2021-01-07 | 96742-2 | SARS-CoV-2 (COVID-19) IgG Ab [Mass/volume] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG | MCnc | Pt | Ser/Plas | Qn | IA | SARS-CoV-2 IgG SerPl IA-mCnc |
2021-01-06 | 96741-4 | SARS-CoV-2 (COVID-19) variant [Type] in Specimen by Sequencing | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 variant | Type | Pt | XXX | Nom | Sequencing | SARS-CoV-2 variant Spec Seq |
2020-12-18 | 96736-4 | COVID-19 Procedure note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Procedure note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Proced note |
2020-12-18 | 96737-2 | COVID-19 Consultation note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Consultation note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Consult note |
2020-12-18 | 96740-6 | COVID-19 note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19 note | Find | Pt | {Setting} | Doc | {Role} | COVID19 note |
2020-12-18 | 96739-8 | Telehealth COVID-19 note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19 note | Find | Pt | Telehealth | Doc | {Role} | Telehealth COVID19 note |
2020-12-18 | 96738-0 | COVID-19 letter | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19 letter | Find | Pt | {Setting} | Doc | {Role} | COVID19 letter |
TIP Click on headings to sort table by that column. Hold down Shift and click additional headings to add to sorting.
TIP In your web browser, use ControlF (or ⌘F on Mac) to find text on this page.
Receive notices of new and revised Special Use prerelease codes
Sign up to receive an email notification when new prerelease Special Use LOINC terms are created or revised.
For timely updates, follow @LOINC on Twitter. An RSS feed of new Special Use terms is also available.